Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks

被引：3
作者：
Bayle, Arnaud [1 ,2 ,3 ,4 ]
Hollebecque, Antoine [1 ]
Pistilli, Barbara [5 ]
Massard, Christophe [1 ]
Marabelle, Aurelien [1 ,6 ]
机构：
[1] Gustave Roussy, DITEP, 114 Rue Edouard Vaillant, F-94805 Villejuif, France
[2] Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France
[3] Univ Paris Saclay, Gustave Roussy, Serv Biostat & Epidemiol, Villejuif, France
[4] Univ Paris Saclay, INSERM, Oncostat U1018, Equipe Labellisee Ligue Canc, Villejuif, France
[5] Gustave Roussy, Dept Med Oncol, Villejuif, France
[6] Soc Francaise Immunotherapie Canc FITC, Lyon, France
来源：
EUROPEAN JOURNAL OF CANCER | 2021年 / 156卷
关键词：
D O I：
10.1016/j.ejca.2021.06.044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：217 / 221
页数：5
相关论文
共 10 条
  • [1] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
    Andre, T.
    Shiu, K-K
    Kim, T. W.
    Jensen, B., V
    Jensen, L. H.
    Punt, C.
    Smith, D.
    Garcia-Carbonero, R.
    Benavides, M.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Bendell, J.
    Le, D. T.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Marinello, P.
    Diaz, L. A., Jr.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) : 2207 - 2218
  • [2] [Anonymous], LIBTAYO CEMIPLIMAB
  • [3] [Anonymous], Guidelines, tools, & resources
  • [4] [Anonymous], EFFICACY LAROTRECTIN, DOI [10.1056/NEJMoa1714448, DOI 10.1056/NEJMOA1714448]
  • [5] [Anonymous], PIQRAY (alpelisib)
  • [6] [Anonymous], LAROTRECTINIB TREATI
  • [7] ESMO, Guidelines
  • [8] Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
    Jacquet, Emmanuelle
    Kerouani-Lafaye, Ghania
    Grude, Francoise
    Goncalves, Sergio
    Lorence, Annie
    Turcry, Florence
    Brunel, Liora
    Belgodere, Laetitia
    Monard, Adrien
    Guyader, Gaelle
    Boudali, Lotfi
    Albin, Nicolas
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 149 : 82 - 90
  • [9] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    [J]. LANCET, 2018, 391 (10126) : 1163 - 1173
  • [10] Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
    Von Hoff, Daniel D.
    Ervin, Thomas
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey
    Moore, Malcolm
    Seay, Thomas
    Tjulandin, Sergei A.
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Dowden, Scot
    Laheru, Daniel
    Bahary, Nathan
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Goldstein, David
    Van Cutsem, Eric
    Wei, Xinyu
    Iglesias, Jose
    Renschler, Markus F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18) : 1691 - 1703
1